Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2708989 | 1.00 | POLB (0.48) | POLBSYKALDH1A1SMN1; SMN2GAA | |
| SCHEMBL20272638 | 0.84 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL30863382 | 0.81 | ABCB1 (0.49) | POLBSYKALDH1A1SMN1; SMN2 | |
| SCHEMBL30878162 | 0.81 | POLB (0.47) | POLBSYKALDH1A1SMN1; SMN2 | |
| SCHEMBL19456479 | 0.81 | POLB (0.47) | POLBSYKALDH1A1SMN1; SMN2NTSR1 | |
| SCHEMBL30307663 | 0.81 | POLB (0.47) | POLBSYKALDH1A1SMN1; SMN2 | |
| SCHEMBL2499502 | 0.81 | POLB (0.47) | POLBSYKALDH1A1SMN1; SMN2 | |
| SCHEMBL2136696 | 0.81 | POLB (0.46) | POLBSYKALDH1A1GAANTSR1 | |
| SCHEMBL2138277 | 0.81 | POLB (0.46) | POLBSYKALDH1A1GAANTSR1 | |
| SCHEMBL12345526 | 0.80 | ALDH1A1 (0.51) | POLBSYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | POLB 4068/4885SYK 1989/4885ALDH1A1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.